Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,916.30 | 90.50 | -1.00% |
CAC 40 | 7,822.67 | 0.67 | 0.01% |
DAX 40 | 24,289.51 | 81.42 | -0.33% |
Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
FTSE 100 | 8,992.12 | 19.48 | 0.22% |
HKSE | 24,895.20 | 69.54 | 0.28% |
NASDAQ | 20,895.65 | 10.01 | 0.05% |
Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
NZX 50 Index | 12,943.97 | 63.57 | 0.49% |
S&P 500 | 6,296.79 | 0.57 | -0.01% |
S&P/ASX 200 | 8,659.40 | 97.80 | -1.12% |
SSE Composite Index | 3,549.89 | 15.41 | 0.44% |